| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cellectar Biosciences Inc (NASDAQ: CLRB)
CLRB Technical Analysis
4
| As on 9th Jun 2023 CLRB STOCK Price closed @ 1.84 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.73 & Strong Buy for SHORT-TERM with Stoploss of 0.59 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CLRBSTOCK Price
| Open | 1.76 | Change | Price | % |
| High | 1.84 | 1 Day | 0.08 | 4.55 |
| Low | 1.74 | 1 Week | 0.28 | 17.95 |
| Close | 1.84 | 1 Month | 0.31 | 20.26 |
| Volume | 13994 | 1 Year | 1.17 | 174.63 |
| 52 Week High 6.37 | 52 Week Low 0.35 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CLRB Daily Charts |
CLRB Intraday Charts |
Whats New @ Bazaartrend |
CLRB Free Analysis |
|
|
CLRB Important Levels Intraday
| RESISTANCE | 2.03 |
| RESISTANCE | 1.97 |
| RESISTANCE | 1.93 |
| RESISTANCE | 1.89 |
| SUPPORT | 1.79 |
| SUPPORT | 1.75 |
| SUPPORT | 1.71 |
| SUPPORT | 1.65 |
CLRB Forecast May 2024
| 4th UP Forecast | 2.28 |
| 3rd UP Forecast | 2.14 |
| 2nd UP Forecast | 2.05 |
| 1st UP Forecast | 1.97 |
| 1st DOWN Forecast | 1.71 |
| 2nd DOWN Forecast | 1.63 |
| 3rd DOWN Forecast | 1.54 |
| 4th DOWN Forecast | 1.4 |
CLRB Weekly Forecast
| 4th UP Forecast | 2.03 |
| 3rd UP Forecast | 1.97 |
| 2nd UP Forecast | 1.93 |
| 1st UP Forecast | 1.89 |
| 1st DOWN Forecast | 1.79 |
| 2nd DOWN Forecast | 1.75 |
| 3rd DOWN Forecast | 1.71 |
| 4th DOWN Forecast | 1.65 |
CLRB Forecast2024
| 4th UP Forecast | 14.21 |
| 3rd UP Forecast | 10.24 |
| 2nd UP Forecast | 7.79 |
| 1st UP Forecast | 5.34 |
| 1st DOWN Forecast | -1.66 |
| 2nd DOWN Forecast | -4.11 |
| 3rd DOWN Forecast | -6.56 |
| 4th DOWN Forecast | -10.53 |
Cellectar Biosciences Inc ( NASDAQ USA Symbol : CLRB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CLRB Business Profile
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; and IntoCell Inc. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service